Monoclonal antibodies in the treatment of cancer, Part 2

Cersosimo, Robert J.

doi:10.1093/ajhp/60.16.1631

Cited by 29 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, we examined IRs among patients receiving their first MoAb infusion. Although IRs may be more common during the first infusion [2,3], the cost of treating IRs after patients have received one or more cycles of chemotherapy may differ from the cost observed in this study. The CTC 3.0 criteria used to define reaction symptoms were those associated with cytokine reaction syndrome, as opposed to criteria for 'allergic reaction.'…”

Section: Discussionmentioning

confidence: 60%

“…The advent of monoclonal antibody (MoAb) technology [9] has led to the development of antibody-mediated cancer therapies within the last decade [2,3]. MoAbs treat cancers by targeting specific antigens or receptors located on malignant cells, whereas conventional chemotherapy does not distinguish between malignant and normal cells [3,13,15].…”

Section: Introductionmentioning

confidence: 99%

“…However, patients with cancer receiving MoAbs are at risk for developing infusion reactions (IRs), immunologic responses that can result from the intravenous administration of any therapeutic agent. IRs are most common during the first infusion and occur less frequently with subsequent infusions [2,3]. National Cancer Institute grades IRs using the five-point Common Terminology Criteria (CTC) for Adverse Events, version 3.0 for cytokine release syndromes/acute infusion reactions, where grade 1 represents a mild IR and grade 5 indicates death [10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study

Schwartzberg

Stepanski

Walker

et al. 2008

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study

Schwartzberg

Stepanski

Walker

et al. 2008

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The most common cardiac adverse effect of therapy by Etoposide , mainly used for refractory testicular tumors and small-cell lung carcinoma, is arterial hypotension but myocardial ischemia may be observed [21]. Monoclonal Antibodies (Alemtuzumab, Bevacizumab, Cetuximab, Rituximab), modernly applied for treatment of some hematologic malignancies and solid tumors, have toxicity profiles specific to the blocked receptors but all produces arterial hypotension [22]. In this category, Trastuzumab, recombinant IgG1 monoclonal antibody binding selectively to the human epidermal growth factor receptor 2 protein and approved for treatment of breast cancer that overexpresses HER2, has a recognized incidence of congestive heart failure [23].…”

Section: Cardiac Toxicity Of Chemotherapic Agents and Radiation Therapymentioning

confidence: 99%

Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography

Galderisi

Marra

Esposito

et al. 2007

Cardiovasc Ultrasound

View full text Add to dashboard Cite

Cancer therapy has shown terrific progress leading to important reduction of morbidity and mortality of several kinds of cancer. The therapeutic management of oncologic patients includes combinations of drugs, radiation therapy and surgery. Many of these therapies produce adverse cardiovascular complications which may negatively affect both the quality of life and the prognosis. For several years the most common noninvasive method of monitoring cardiotoxicity has been represented by radionuclide ventriculography while other tests as effort EKG and stress myocardial perfusion imaging may detect ischemic complications, and 24-hour Holter monitoring unmask suspected arrhythmias. Also biomarkers such as troponine I and T and B-type natriuretic peptide may be useful for early detection of cardiotoxicity. Today, the widely used non-invasive method of monitoring cardiotoxicity of cancer therapy is, however, represented by Doppler-echocardiography which allows to identify the main forms of cardiac complications of cancer therapy: left ventricular (systolic and diastolic) dysfunction, valve heart disease, pericarditis and pericardial effusion, carotid artery lesions. Advanced ultrasound tools, as Integrated Backscatter and Tissue Doppler, but also simple ultrasound detection of "lung comet" on the anterior and lateral chest can be helpful for early, subclinical diagnosis of cardiac involvement. Serial Doppler echocardiographic evaluation has to be encouraged in the oncologic patients, before, during and even late after therapy completion. This is crucial when using anthracyclines, which have early but, most importantly, late, cumulative cardiac toxicity. The echocardiographic monitoring appears even indispensable after radiation therapy, whose detrimental effects may appear several years after the end of irradiation.

show abstract

“…Eighty seven per cent of patients experience infusion-related side effects, such as fevers, chills and rigours; these commonly occur within the first few hours, especially during the first infusion. Less severe reactions such as hypotension, angioedema, hypoxia or bronchospasm can be seen in up to 10% of cases 10. These symptoms are associated with cytokine release, particularly IL-6.…”

Section: Discussionmentioning

confidence: 99%

Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?

Dearden

Gruber

2015

BMJ Case Reports

View full text Add to dashboard Cite

Rituximab is used for treatment of multiple haematological cancers. Caution for use is advised in patients with significant cardiorespiratory disease due to known cases of exacerbations of angina and arrhythmias. However, its cardiotoxicity profile is not as well recognised as other monoclonal antibodies such as transtuzumab. We report a case of a 66-year-old man who developed Takotsubo's cardiomyopathy (TC) after an elective infusion of rituximab. This case is exceptional in that rituximab has not been linked to TC, and the vast majority of chemotherapy-linked and immunotherapy-linked TC reactions have occurred during initial infusions. We also discuss the different mechanisms which link TC to immunotherapy and chemotherapy, and propose that there may be a potential for risk-stratifying recipients of this frequently used immunotherapy prior to administering treatment.

show abstract

Monoclonal antibodies in the treatment of cancer, Part 2

Cited by 29 publications

References 0 publications

Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study

Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study

Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography

Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?

Contact Info

Product

Resources

About